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Thrombin stimulates proinflammatory and proliferative re-
sponses in primary cultures of human proximal tubule cells.
Background. Fibrin deposition is frequently observed within
the tubulointerstitium in various forms of chronic renal dis-
ease. This suggests the presence of active components of the
coagulation pathway, which may contribute to the progressive
deterioration in renal function. The aim of this study was to in-
vestigate the proinflammatory and fibroproliferative effects of
the coagulation protease thrombin on human proximal tubular
cells (PTC) in culture.
Methods. Primary cultures of PTC were established from
normal kidney tissue and grown under serum-free conditions
with or without thrombin or the protease-activated receptor
(PAR) activating peptides TFLLRN-NH2, SLIGKV-NH2, and
SFLLRN-NH2 (100 to 400 lmol/L). DNA synthesis (thymi-
dine incorporation), intracellular Ca2+ mobilization (fura-2
fluorimetry), fibronectin secretion [enzyme-linked immunosor-
bent assay (ELISA), immunoblotting], monocyte chemoattrac-
tant protein-1 (MCP-1) secretion (ELISA), and transforming
growth factor-b1 (TGF-b1) secretion (ELISA) were measured.
Reverse transcription-polymerase chain reaction (RT-PCR)
was used to assess PAR mRNA expression in these cells.
Results. Thrombin enhanced DNA synthesis, fibronectin
secretion, MCP-1 secretion, and TGF-b1 secretion in a
concentration-dependent manner. Cell injury [lactate dehydro-
genase (LDH) release] and cellular protein levels were unaf-
fected. RT-PCR showed that cultures of PTC expressed mRNA
transcripts for the thrombin receptors PAR-1 and PAR-3, but
not PAR-4. Thrombin and each of the PAR activating pep-
tides enhanced intracellular calcium mobilization. However,
the other effects of thrombin were only fully reproduced by
the PAR-2–specific peptide, SLIGKV-NH2, only partially by
SFLLRN-NH2, (a PAR-1 peptide that can activate PAR-2),
and not at all by the PAR-1–specific peptide, TFLLRN-NH2.
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Thrombin-induced DNA synthesis, fibronectin, and MCP-1 se-
cretion were unaffected by a TGF-b neutralizing antibody,
the matrix metalloproteinase (MMP) inhibitor, GM6001 and
the epidermal growth factor (EGF) receptor kinase inhibitor
AG1478.
Conclusion. Thrombin initiates both proinflammatory and
fibroproliferative responses in human PTC. These responses
which are dependent on its protease activity appear not to
be mediated by PAR-1 activation, the autocrine action of
thrombin-induced TGF-b1 secretion, MMP activation, or EGF
receptor transactivation. The proinflammatory and fibroprolif-
erative actions of thrombin on human PTC may help explain the
extent of tubulointerstitial fibrosis observed in kidney diseases
where fibrin deposition is evident.
Fibrotic disorders of the kidney and other organs (such
as the liver and lung) are frequently associated with acti-
vation of the coagulation cascade, culminating in the local
generation of activated clotting factors, such as thrombin,
factor Xa, and fibrin [1–6]. Persistent fibrin deposition has
generally been observed within the interstitial space and
peritubular capillaries in many forms of renal disease,
including ischemic nephropathy, obstructive nephropa-
thy, chronic renal allograft nephropathy, and primary and
secondary forms of glomerulonephritis [1–7]. However,
the mechanisms responsible for this event and its patho-
genetic relevance to tubulointerstitial scarring have not
been formally studied. Attempts to prevent renal disease
progression with nonspecific anticoagulation have largely
been abandoned because of serious side effects, primarily
bleeding [2, 8].
A potential link between coagulation, inflammation,
and fibrosis has recently been suggested to occur via a
novel family of cell surface, G protein–coupled recep-
tors, known as protease-activated receptors (PARs) [9].
Cleavage of the N-terminal exodomain of the receptor
reveals a new N-terminus, which acts as a tethered lig-
and. Four distinct PARs have been described [10, 11].
PAR-1, -3 and -4 are activated by thrombin, while PAR-2
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acts as a receptor for serine proteases other than throm-
bin (principally mast cell tryptase, trypsin, and clotting
factors Xa and VIIa). Activation of PARs by activated
clotting factors or other serine proteases has increasingly
been recognized in nonrenal studies to result in activation
of inflammatory cells such as monocytes, T lymphocytes
and mast cells, and proliferation of other cell types, in-
cluding endothelial cells, fibroblasts, and smooth muscle
cells [12, 13].
Thrombin receptors are widely expressed within the
kidney. PAR-1 is expressed by glomerular endothelial,
mesangial, and tubule cells [7, 14, 15]. The expression
of PAR-3 and -4 have been demonstrated in the kid-
ney but they have not been studied in detail [16, 17].
In patients with chronic allograft nephropathy, tubular
expression of PAR-1 is markedly up-regulated and cor-
relates with interstitial fibrin deposition, the degree of
tubulointerstitial fibrosis, and urinary excretion of trans-
forming growth factor-b (TGF-b) [18]. Moreover, in a
murine model of crescentic glomerulonephritis, the use
of hirudin (a selective antagonist of thrombin-induced
proteolytic activation of PARs), or PAR-1 knockout mice
equally effectively reduced crescent formation, glomeru-
lar inflammatory cell infiltration, and serum creatinine
concentrations. Conversely, administration of a selective
PAR-1–activating peptide augments histologic and func-
tional injury [19].
The known cellular actions of PAR activation ap-
pear to be mediated either directly via intracellular
signaling pathways [including mitogen-activated pro-
tein (MAP) kinases, phospholipase C, protein kinase C,
cyclooxygenase-2 (COX-2), and peroxisome proliferator
activated receptor-gamma (PPARc)] [10, 11] or indirectly
via the induction of fibrogenic cytokines, such as TGF-b ,
platelet-derived growth factor (PDGF), fibroblast growth
factor (FGF), and prostaglandin E2 [20–23]. There is also
accumulating in vivo evidence that acute or persistent
PAR activation contributes to aberrant tissue repair and
fibrosis in a number of pathologic conditions, including
restenosis and neointima formation following vascular in-
jury [24, 25], atherosclerosis [26], and pulmonary fibrosis
[27].
The present study examined the action of the serine
protease thrombin on human PTC in culture. We were
particularly interested in how thrombin might influence
cellular DNA synthesis, the production of extracellular
matrix (ECM) protein fibronectin, the chemotactic and
proinflammatory molecule monocyte chemoattractant
protein-1 (MCP-1) and the potentially fibrogenic growth
factor TGF-b1. Using PAR-specific peptides we at-
tempted to link the responses of these cells to thrombin,
to PAR-1 activation. In addition, the possibilities that the
actions of thrombin are mediated indirectly through the
autocrine action of TGF-b , the activation of matrix met-
alloproteinases (MMP) and/or epidermal growth factor
(EGF) receptor transactivation were investigated.
METHODS
Chemicals
Cell culture tested thrombin purified from human
plasma (1000 N IU/mg protein, catalog number T4393)
and hirudin (11,500 U/mg, catalog number H0393) were
purchased from Sigma Chemical Co. (St. Louis, MO,
USA). The PAR activating peptides SFLLRN-NH2,
TFLLRN-NH2, and SLIGKV-NH2 were synthesized
with carboxyl-terminal amidation and purified to >95%
via high-performance liquid chromatography (HPLC) by
Auspep Ltd. (Melbourne, Australia). The MMP inhibitor,
GM6001, and EGF receptor kinase inhibitor, AG1478,
were purchased from Merck (San Diego, CA, USA).
Cell culture
Segments of macroscopically and histologically nor-
mal renal cortex (5 to 10 g) were obtained aseptically
from adult human kidneys removed surgically for ei-
ther small (<6 cm) renal adenocarcinomas or benign re-
nal cysts. Patients were otherwise healthy and were on
no medications. Informed consent was obtained prior to
each operative procedure and the use of human renal
tissue for primary culture was reviewed and approved
by the Princess Alexandra Hospital Research Ethics
Committee.
The method for primary culture of human PTC is
described in detail elsewhere [28, 29]. Briefly, renal
cortical tissue was dissected from the medulla, minced,
digested with collagenase (class 2, 200 to 383 U/mg)
(Worthington, Freehold, NJ, USA) and passed through
a 100 lm mesh. Filtered cells were resuspended in
45% Percoll (Amersham-Pharmacia-Biotech, Uppsala,
Sweden) and separated into four distinct bands by isopy-
cnic centrifugation. The lowermost band was removed
for PTC culture. PTC were resuspended in serum-free,
hormonally defined Dulbecco’s modified Eagle’s medium
(DMEM)/F-12 media (Thermo Electron Corporation,
Melbourne, Australia), supplemented with penicillin
(50 U/mL), streptomycin (50 lg/mL), human transfer-
rin (5 lg/mL), bovine insulin (0.87 lmol/L), hydrocor-
tisone (0.05 lmol/L), EGF (10 ng/mL) (Collaborative
Research Inc., Bedford, MA, USA), prostaglandin E1
(50 nmol/L) (Sigma Chemical Co.), selenium (50 nmol/L)
and tri-iodothyronine (5 pmol/L) (Sigma Chemical Co.).
The tubular fragments were plated at a density of 1.5 mg
pellet/cm2 (approximately 5000 fragments/cm2) in 75 cm2
flasks. Cells were incubated in humidified atmosphere of
95% air/5% CO2 at 37◦C and media changed every 48
hours. Confluence was reached at approximately 10 days
after plating. Cells were passaged using Dispase II (Roche
Diagnostics, Indianapolis, IN, USA) and frozen cultures
maintained in liquid nitrogen.
Cytologic examination of PTC preparations from
all donors failed to reveal any evidence of cellular
atypia. The morphologic, biochemical, and functional
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characteristics of these cells have been previously stud-
ied in this laboratory and found to reproducibly exhibit
the features of PTC in vivo [28]. Specifically, these cells
exhibit typical cobblestone morphology along with in-
tact tight junctions, parathyroid hormone (PTH) (but not
vasopressin), response, cyclic adenosine monophosphate
(cAMP) production and polarized transport systems,
including pharmacologically distinct apical and baso-
lateral sodium-hydrogen exchange, phlorizin-inhibitible
apical Na+-glucose transport, PTH-inhibitable apical
Na+-phosphate transport, probenecid-inhibitable vecto-
rial organic anion transport, and quinine-inhibitable vec-
torial organic cation transport. Fibroblast, mesangial, and
endothelial cell contamination was negligible, as evi-
denced by the uniform negative staining of cultures for
vimentin, desmin, and factor VIII, respectively [28].
Experimental protocol
All experiments were performed on confluent, pas-
sage 2 PTC cultured in 48-, 24-, or 6-well tissue culture
plates. Cells were made quiescent by two washes followed
by incubation for 24 hours in basic media (DMEM/F-
12 containing 5lg/mL transferrin). The concentration-
dependent effects of thrombin or the PAR-1 peptides,
TFLLRN-NH2 and SFLLRN-NH2, or PAR-2 peptide,
SLIGKV-NH2, on DNA synthesis, fibronectin produc-
tion, MCP-1 expression and TGF-b1 production were
then assessed over a 24-hour period. The influence of the
thrombin inhibitor, hirudin, a MMP inhibitor, GM6001,
an EGF receptor kinase inhibitor, AG1478, and a TGF-
b neutralizing antibody on these responses to thrombin
was assessed. Media conditioned by PTC were harvested,
mixed with a cocktail of protease inhibitors, and stored
at −80◦C until assayed.
Fibronectin determination
The fibronectin concentration in the culture super-
natant was determined using a sandwich enzyme-linked
immunosorbent assay (ELISA) [30, 31]. The wash buffer
used was phosphate-buffered saline (PBS) containing
0.05% Tween-20, pH 7.4. The coating buffer was car-
bonate/bicarbonate (0.05 mol/L carbonate), pH 9.7. Each
well of a flat bottomed 96-well microtitre plate (Nalge
Nunc International, Naperville, IL, USA) was coated
with 100 lL of rabbit antihuman fibronectin (Dako Cy-
tomation, Botany, NSW, Australia) diluted to a concen-
tration of 10 mg/mL in coating buffer for 24 hours at 4◦C.
The plates were then washed four times with wash buffer.
Appropriately diluted test samples were then added to
the assay plate along with fibronectin standards (1 to
800 ng/mL). The plates were incubated for 2 hours at
room temperature and then washed a further four times
with wash buffer. One hundred microliters of the sec-
ondary peroxidase-conjugated antihuman fibronectin an-
tibody (Dako) diluted 1/4000 in PBS containing 0.05%
Tween-20 were then added to each well of the plate.
After a further 1-hour incubation at room temperature,
plates were washed as before and then incubated with
1,2-phenylene diamine dihydrochloride (OPD) substrate
(Dako) according to the manufacturer’s instructions. The
reaction was stopped with 100 lL of 0.5 mol/L sulphuric
acid and the absorbance determined at 492 nm. A stan-
dard curve was constructed and unknowns determined
from this curve. The intra- and interassay variation at 50
ng/mL was less than 12%.
MCP-1 determination
MCP-1 was measured in the culture medium from PTC
using a specific ELISA (R&D Systems, Minneapolis, MN,
USA) according to the manufacturer’s protocols.
Measurement of TGF-b in conditioned media
TGF-b( levels in PTC-conditioned media were mea-
sured using a commercially available ELISA kit (R&D
Systems). Total (active plus latent) TGF-b1 was deter-
mined following transient acidification of conditioned
media. Briefly, each mL of conditioned medium was incu-
bated with 100 lL of 1 mol/L HCl for 15 minutes at room
temperature, followed by neutralization with an equiv-
alent volume of 1.2 mol/L NaOH/0.5 mol/L Hepes. The
minimum detectable concentration of TGF-b1 by the as-
say was 15 pmol/L.
Western blot analysis
On some occasions, secreted and cell associated fi-
bronectin were determined by Western blot analysis.
Equal amounts of conditioned media, or in the case of cell
lysate, cell protein, were diluted in a reducing sodium do-
decyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) sample buffer, heated to 70◦C for 10 minutes,
separated on a 4% to 12% NUPAGE Gel (Invitro-
gen, Melbourne, Australia) and then electrotransferred
to a polyvinlydine difluoride (PVDF) membrane. Mem-
branes were blocked overnight with 5% skim milk pow-
der in PBS containing 0.1% Tween-20. The primary mon-
oclonal fibronectin antibody (Becton & Dickinson, North
Ryde, New South Wales, Australia) was added, in block-
ing buffer for 1 hour. An antimouse peroxidase conju-
gate (Bio-Rad Laboratories, Regents Park, New South
Wales, Australia) was used at recommended dilutions for
the secondary antibody. Detection was with enhanced
chemiluminescence (ECL)-plus (Amersham-Pharmacia-
Biotech, Amersham, UK). To control for equal protein
loading and transfer the membrane was stripped using
Re-Blot Plus Mild (Chemicon, Temecula, CA, USA) ac-
cording to the supplied instructions and reprobed with a
pan-actin primary antibody (NeoMarkers, Fremont, CA,
USA) in blocking buffer for 1 hour. The actin bands were
visualized as above.
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Cell growth
PTC damage was assessed using a cytotoxicity de-
tection kit (Roche, Dee Why, New South Wales, Aus-
tralia) which measures lactate dehydrogenase (LDH)
release into the culture media. Manufacturer’s pro-
tocols were followed. Cell counts were performed
at the conclusion of selected experiments using a
hemocytometer. Tritiated thymidine incorporation into
cellular DNA, an index of DNA synthesis, was mea-
sured according to a previously described method [30].
Briefly, cells were incubated with control or test me-
dia for 24 hours. For the final 4 hours of this culture
[methyl-3H]-thymidine (Amersham-Pharmacia-Biotech,
Uppsala, Sweden), 4 lCi (0.15 MBq) per mL of media
were added. At the end of the test period cells were
washed twice with ice-cold PBS, thrice with ice-cold 10%
trichloroacetic acid (TCA) for 20 minutes, and once with
methanol. Monolayers were allowed to dry and then dis-
solved in 300 lL of 0.3 mol/L NaOH containing 1% SDS.
Aliquots of cell lysate were taken for liquid scintillation
counting in a b counter. Results were corrected for cellu-
lar protein content. The protein content of the cell lysate
was measured by a commercially available protein assay
using bovine serum albumin (BSA) as the standard.
Detection of PAR mRNA using reverse
transcription-polymerase chain reaction (RT-PCR)
Human primary PTCs were grown to confluence as
described above. Total RNA was extracted from the
cells using the RNeasy Mini Kit (Qiagen, Duncaster,
Victoria, Australia) according to the manufacturer’s
protocols. During the isolation the RNA was subjected
to DNase digestion. Two micrograms of RNA were
converted into cDNA using Expand Reverse Tran-
scriptase (Roche) with standard methodologies. PCR
was performed in a total reaction volume of 25 lL
containing 1 × PCR buffer, 1 lL of cDNA, 12.5 pmol
of each primer, 1.5 mmol/L MgCl2, and 0.625 U of Taq
DNA polymerase (Red Hot DNA Polymerase) (AB
Gene, Epsom, Surrey, UK). The PAR and hypoxanthine
phosphoribosyltransferase (HPRT) primer sequences
and thermal cycling temperatures have been previously
published [30, 32, 33] and are given as follows: PAR-1
primers 1st 5′-TGTGAACTGATCATGGTTATG-3′
and 5′-TTCGTAAGATAAGAGAATATGT-3′ (708 bp
product), 1 × 94◦C for 5 minutes; 30 × 94◦C for 1 minute,
55◦C for 1 minute, and 72◦C for 1 minute; PAR-1 primers
2nd 5′-CCACAAACGTCCTCCTGATT-3′ and 5′-
TGGGATCGGAACTTTCTTTG-3′ (200 bp product),
same conditions as for the first set of PAR-1 primers;
PAR-2 primers 5′-AGAAGCCTTATTGGTAAGGTT-
3′ and 5′-AACATCATGACAGGTCGTGAT-3′ (582 bp
product), 1 × 94◦C for 5 minutes, 35 × 94◦C for 1
minute, 55◦C for 1 minute, and 72◦C for 1 minute; PAR-3
primers 5′-CTGATACCTGCCATCTACCTCC-3′ and
5′-AGAAAACTGTTGCCCACACC-3′ (382 bp prod-
uct), 1 × 94◦C for 5 minutes, 35 × 94◦C for 1 minute,
65◦C for 1 minute, and 72◦C for 1 minute; PAR-4 primers
5′-ATTACTCGGACCCGAGCC-3′ and 5′-TGTAAGG
CCCACCCTTCTC-3′ (392 bp product), 1 × 94◦C for
5 minutes; 35 × 94◦C for 1 minute, 65◦C for 1 minute,
and 72◦C for 1 minute; and HPRT primers 5′-AAT
TATGGACAGGACTGAACGTC-3′ and 5′-CGTGGG
GTCCTTTTCACCAGCAAG-3′ (386 bp product), 1 ×
94◦C for 5 minutes, 25 × 94◦C for 1 minute, 64◦C for
1 minute, and 72◦C for 1minute.
PCR products were separated on 1.8% agarose gels
containing 1 lg of ethidium bromide per mL in 1 ×
Tris borate-EDTA (TBE) buffer and viewed and pho-
tographed under ultraviolet light. A HaeIII digest of φ×
174 was used as a marker.
Measurement of cytosolic Ca2+
Intracellular Ca2+ measurements were performed us-
ing the fluorescent ratiometic Ca2+ dye Fura-2 (Fura-2
AM) (Molecular Probes, Eugene, OR, USA) in 96-well
plates. Cells were grown to confluence in sterile, tis-
sue culture treated black 96-well plates (Perkin-Elmer
Life and Analytical Sciences, Victoria, Melbourne, Aus-
tralia). Before experimentation cells were incubated for
24 hours in basic media, then washed twice in Tyrode
buffer (137 mmol/L NaCl, 5 mmol/L KCl, 2 mmol/L CaCl,
1 mmol/L MgCl, 10 mmol/L D-glucose, 10 mmol/L Hepes,
and NaOH, pH 7.4), and loaded with 5 lmol/L Fura-2 in
the same buffer for 1 hour at 37◦C with shaking. After
loading, cells were washed twice in Tyrode buffer to re-
move excess dye. All experiments were performed in a
BMG Fluostar Optima (BMG Lab Technologies, Offen-
burg, Germany) using 340 nm, 380 nm excitation, and 520
nm emission filters (BMG Lab Technologies). An auto-
mated injection of agonist was made to give overall con-
centrations of thrombin (5 U/mL), SFLLRN-NH2 (100
lmol/L), TFLLRN-NH2 (100 lmol/L), and SLIGKV-
NH2 (100 lmol/L) in the corresponding wells. The ratio of
the excitation wavelengths at 340/380 nm represents the
change in intracellular Ca2+ in response to the agonist.
Statistical analysis
All studies were performed in triplicate from PTC cul-
tures obtained from at least three separate human donors.
Each experiment contained internal controls originat-
ing from the same culture preparation. For the purposes
of analysis, each experimental result was expressed as
a change from the control value, which was regarded
as 100%, and analyzed independently. Results are ex-
pressed as mean ± SEM. Statistical comparisons between
two groups were made using unpaired t tests. Multi-
ple group comparisons were made by analysis of vari-
ance (ANOVA). The software package SPSS version 11.5
(SPSS, Inc., Chicago, IL, USA) was used. P values less
than 0.05 were considered significant.
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RESULTS
Human PTC expressed thrombin receptors 1 and 3
Using conventional RT-PCR, primary cultures of hu-
man PTC were found to express mRNA transcripts for
thrombin receptors PAR-1 and PAR-3 but not PAR-4
(Fig. 1A). PAR-2 mRNA is also expressed by these cells.
As there has been some controversy [7, 14, 34] with regard
to PAR-1 expression in PTC these results were confirmed
with a second set of PAR-1 specific primers (Fig. 1B).
To exclude the possibility that the PCR products repre-
sented amplification of contaminating genomic DNA, all
isolated RNA was pretreated with DNase according to
the manufacturer’s protocol. In addition, control reverse
transcriptase reactions were performed in the absence of
reverse transcriptase enzyme, in which case no PAR PCR
signals were observed (Fig. 1C).
Thrombin stimulates mobilization of calcium
from internal stores
Calcium mobilization assays have been widely used to
study PAR activation. To establish that functional throm-
bin receptors are present on PTCs, cells were cultured
with thrombin or PAR peptides and relative changes in
intracellular free calcium levels monitored. Treatment
of PTC with either thrombin (5 U/mL), TFLLRN-NH2
(100 lmol/L), SFLLRN-NH2 (100 lmol/L), or SLIGKV-
NH2 (100 lmol/L) caused a rapid rise in free intracel-
lular calcium concentrations as indicated by enhanced
Fura-2 AM fluorescence (Fig. 2A). The relative Fura-
2 fluorescence ratio reached a peak at 17 seconds after
treatment. Of the agonists tested, SLIGKV-NH2 induced
the largest increase in calcium mobilization. Throm-
bin and SFLLRN-NH2 both produced similar signals at
about 52% of that produced by SLIGKV-NH2. The cal-
cium response to TFLLRN-NH2 was only 34% of that
produced by SLIGKV-NH2 (Fig. 2B).
Thrombin stimulates DNA synthesis in human PTC
As thrombin and PAR-1 peptides have been shown
to stimulate proliferation in a range of fibroblastic
and epithelial cell types [15, 21, 22, 35], the effect of
thrombin/SFLLRN-NH2/TFLLRN-NH2 on DNA syn-
thesis in primary PTC cultures was investigated. This
was achieved by culturing confluent, quiescent cells
with thrombin (0.01 to 8 U/mL), SFLLRN-NH2 (100 to
400 lmol/L), or TFLLRN-NH2 (100 to 400 lmol/L), and
measuring 3[H]-thymidine incorporation into DNA over
the final 4 hours of a 24-hour test period. Thrombin stimu-
lated DNA synthesis in primary cultures of PTC (Fig. 3A).
Increases in DNA synthesis were first observed at a con-
centration of 0.5 U/mL and this response increased in a
concentration-dependent fashion up to 8 U/mL; signifi-
cant increases were reached at concentrations of 2 U/mL
200 bp
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Fig. 1. Reverse transcription-polymerase chain reaction (RT-PCR)
analysis of protease-activated receptor (PAR) expression by cultured
human proximal tubule cells (PTCs). Total RNA was isolated from con-
fluent passage 2, human PTC, reverse transcribed, and amplified with
specific primers for PARs and hypoxanthine phosphoribosyltransferase
(HPRT). PCR products were separated on 1.8% agarose gels contain-
ing ethidium bromide and photographed. (A) Expression of thrombin
receptors (PAR-1, PAR-3, and PAR-4), and PAR-2 by PTC. Lane 1,
PAR-1 (200 bp); lane 2, PAR-2 (582 bp); lane 3, PAR-3 (382 bp); lane 4,
PAR-4, (392 bp); lane 5, HPRT (386 bp); and lane 6, X174 DNA/Hae
III markers. (B) Expression of PAR-1 in three different PTC cultures
by two different sets of PAR-1 primers. Lane 1, PTC 1; lane 2, PTC 2;
lane 3, PTC 3; lane 4, negative control; and lane 5, X174 DNA/Hae III
markers. (C) RT-PCR analysis of PAR-1 expression in cells from three
different PTC culture in which the RT step is carried out with (RT) or
without (NRT) the reverse transcriptase enzyme. Lane 1, PTC 1 RT;
lane 2, PTC 1 NRT; lane 3, PTC 2 RT; lane 4, PTC 2 NRT; lane 5, PTC
3 RT; lane 6, PTC 3 NRT; lane 7, negative control; and lane 8, X174
DNA/HaeIII markers.
and above (P < 0.05). Thrombin at 2, 4, and 8 U/mL in-
creased DNA synthesis by 141.2 ± 24%, 187.7 ± 31%,
and 237.2 ± 24% of control values, respectively (Fig. 3A)
(Table 1). The PAR peptide SFLLRN-NH2, in the range
100 to 400 lmol/L, produced significant but lower in-
creases in DNA synthesis; at 100, 200, and 400 lmol/L,
increases in DNA synthesis were 119 ± 17% (NS), 128 ±
7% (P < 0.05), and 140 ± 3% (P < 0.05) of control val-
ues, respectively. On the other hand, the specific PAR-1
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Fig. 2. The effects of thrombin and the protease-activated receptor
(PAR) peptides on calcium mobilization in human proximal tubular
cells (PTCs). Cells were grown to confluence and loaded with Fura-
2 AM. They were then exposed to thrombin (5 U/mL), TFLLRN-
NH2 (100 lmol/L), SFLLRN-NH2 (100 lmol/L), SLIGKV-NH2 (100
lmol/L), or VKGILS-NH2 (100 lmol/L) and intracellular Ca2
+ fluores-
cence measured. (A) The results are expressed as the change from basal
level of the fluorescence ratio (340/380 nm). Each trace is an average
response from cells in four different wells and is representative of two
different experiments. (B) Results are expressed as a percentage of the
SLIGKV-NH2 signal at 24 seconds (17 seconds after agonist addition).
peptide TFLLRN-NH2 was unable to induce significant
increases in DNA synthesis at any concentration tested
(Table 1). Cellular protein levels were not affected by
thrombin (Fig. 3F), SFLLRN-NH2, or TFLLRN-NH2
treatment (data not shown for PAR peptides). The PAR-
2 peptide SLIGKV-NH2 also increased DNA synthesis.
At 100, 200, and 400 lmol/L increases in DNA synthesis
were 123 ± 15% (P < 0.05), 210.9 ± 19.6% (P < 0.01),
and 298.1 ± 27.5% (P < 0.01) of control values, respec-
tively (Table 1). Thrombin failed to significantly increase
PTC numbers after 24-hour culture. Thrombin at 1, 2, and
4 U/mL increase PTC numbers by 125 ± 24% (NS), 128 ±
33% (NS), and 127 ± 40% (NS) of control values, respec-
tively. The average number of cells per well of a 48-well
plate under basal conditions was 173,000 ± 34,600.
Thrombin did not cause cellular damage
To investigate if thrombin caused damage of PTC cul-
tures, LDH release in response to thrombin treatment
was measured. Cells treated with thrombin (0.002 to
8 U/mL) failed to show a significant increase in LDH
release at any dose tested (Fig. 3B). Levels of LDH re-
leased into the media from both treated and untreated
cells were below 8% of total cellular LDH.
Thrombin stimulated fibronectin secretion
by human PTC
Fibronectin is one of the first matrix proteins produced
in response to cell injury and inflammation. It has been
demonstrated to be important in modulating cell migra-
tion, chemotaxis, cell anchorage, and collagen deposition.
The present investigation analyzed whether thrombin
was able to influence fibronectin secretion by primary
PTC. Thrombin enhanced fibronectin secretion by PTC
in a concentration-dependent fashion (Fig. 3C). Signifi-
cant increases in fibronectin secretion were observed at
2 U/mL and reached 263 ± 56% of control values at
a concentration of 16 U/mL. The absolute fibronectin
secretion rate in the control cultures was 0.459 ± 0.41
lg/mg protein/day (N = 7). Immunoblotting demon-
strated enhanced production of a single fibronectin band
at an apparent molecular weight of 220 kD in response
to thrombin treatment. This is shown in Figure 4A for
cells established from the renal cortex of four differ-
ent kidney samples. Fibronectin fragmentation was not
observed. To establish whether this response to throm-
bin was mediated by PAR-1 activation, fibronectin in
the conditioned culture media of PTC exposed to either
SFLLRN-NH2 or TFLLRN-NH2 was measured. While
SFLLRN-NH2 at all concentrations tested significantly
increased fibronectin secretion, the more specific PAR-1
peptide TFLLRN-NH2 was without an effect (Table 1).
In addition, the PAR-2 activating peptide SLIGKV-NH2
at concentrations of 100, 200, and 400 lmol/L significantly
enhanced fibronectin secretion by 160 ± 20% (P < 0.05),
252.7 ± 13% (P < 0.01), and 367.7 ± 48% (P < 0.01) of
control values, respectively (Table 1). It has been reported
that the appearance of increased amounts of fibronectin
in cell culture media in response to thrombin treatment is
accompanied by decreases in cell associated-fibronectin
[36]. Figure 4B demonstrates that this is the case. How-
ever, the decrease in cell-associated fibronectin can not
account for the much greater increase in fibronectin re-
leased in to the media of thrombin treated cells. By com-
parison, TGF-b1 at 5 ng/mL significantly increased both
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Fig. 3. The effect of thrombin on human proximal tubule cell (PTCs) DNA synthesis (A), lactate dehydrogenase (LDH) release (B), fibronectin
secretion (C), monocyte chemoattractant protein-1 (MCP-1) secretion (D), transforming growth factor-b1 (TGF-b1) secretion (E), and cell protein
levels (F). Confluent passage 2 human PTC were treated with or without thrombin for 24 hours and assayed for the above responses as detailed
under the Methods section. Data points are the mean ± SEM from five independent experiments, each performed in triplicate. ∗P < 0.05 vs. control
cells.
cell associated (537 ± 46% of control) and secreted fi-
bronectin (235 ± 12.5% of control).
MCP-1 secretion was stimulated in PTCs treated with
thrombin
There is strong evidence that MCP-1 is an impor-
tant promoter of tubulointerstitial disease. This is not
only due to its potent chemotactic actions for mono-
cytes but also through its direct action on tubulointer-
stitial cells [37–40]. The present investigation examined
whether thrombin could modulate MCP-1 production in
PTCs. We found that thrombin enhanced MCP-1 produc-
tion by human PTC in concentration-dependent manner
(Fig. 3D). A significant increase in MCP-1 secretion was
seen at 0.1 U/mL of thrombin. At the highest concentra-
tion of thrombin tested (8 U/mL) MCP-1 concentrations
were 262 ± 25% of control values. Levels of MCP-1 in the
media of cells treated with thrombin reached 2 ng/mL or
10.5 ± 4 ng/mg cell protein/day. To examine if the PAR-1
peptides, SFLLRN-NH2 and TFLLRN-NH2, can induce
MCP-1 secretion, cells were cultured with these peptides
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Table 1. Comparative responses of human proximal tubule cells (PTCs) to treatment with thrombin and protease-activated receptor (PAR)
peptides
Response (% of control)
Agonist Concentration lmol/L DNA synthesis Fibronectin secretion MCP-1 secretion TGF-b1 secretion
2 U/ml 141 ± 24a 130 ± 18a 217 ± 24a 183 ± 32a
4 U/ml 188 ± 31a 181 ± 27a 242 ± 27a 276 ± 24a
8 U/ml 237 ± 24a 249 ± 55a 262 ± 25a 524 ± 49a
TFLLRN-NH2 100 110 ± 61 127 ± 13 110 ± 19 115 ± 30
200 112 ± 41 92 ± 28 95 ± 25 125 ± 21
400 113 ± 16 105 ± 12 104 ± 28 105 ± 10
SFLLRN-NH2 100 119 ± 17 156 ± 18a 137 ± 32 110 ± 10
200 128 ± 7a 177 ± 20a 144 ± 30 109 ± 5
400 140 ± 3a 189 ± 21a 173 ± 34a 134 ± 9a
SLIGKV-NH2 100 123 ± 15a 160 ± 20a 208 ± 17a 170 ± 23a
200 211 ± 20a 253 ± 13a 245 ± 12a 217 ± 18a
400 298 ± 28a 368 ± 48a 263 ± 25a 301 ± 45a
VKGILS-NH2 200 117 ± 9 103 ± 6.7 125 ± 13 98 ± 8
DNA synthesis, fibronectin secretion, monocyte chemoattractant protein-1 (MCP-1) secretion and transforming growth factor-b1 (TGF-b1) secretion were measured
in confluent passage 2 human PTC treated with thrombin or PAR activating peptides. The results were expressed as a% of the control values (mean ± SEM) for at least
three separate experiments that were performed in triplicate.
aP < 0.05.
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Fig. 4. Analysis of fibronectin secreted by or associated with human
proximal tubular cells (PTCs) treated with thrombin. Confluent, quies-
cent, passage 2 human PTC cultures were treated with (T) or without
(C) thrombin (5 U/mL). After 24 hours, conditioned media and cells
lysate were collected and analyzed by electrophoresis and Western blot
analysis (A and B) using a specific fibronectin antibody. (A) Condi-
tioned media from four different PTC cultures were analyzed. A single
band at 220 kD was observed. No fibronectin degradation products were
apparent.
and MCP-1 secretion into the culture media measured.
TFLLRN-NH2 failed to enhance MCP-1 secretion at
all concentrations tested whereas SFLLRN-NH2 signifi-
cantly increased MCP-1 secretion at 400 lmol/L (173.4 ±
33.5% vs. control) (P < 0.05) (Table 1). The PAR-2 pep-
tide SLIGKV-NH2 significantly stimulated MCP-1 secre-
tion at all concentrations tested (Table 1). At 100 lmol/L,
the MCP-1 concentration in the conditioned media was
increased to 208 ± 16.5% of the control value.
Thrombin induces TGF-b1 secretion by PTC
Thrombin can stimulate TGF-b1 production by mesan-
gial cells and the immortalized tubule cell line, human
kidney-2 (HK-2) [18, 20]. In the present investigation,
we found that thrombin treatment induced a significant
increase in TGF-b1 production by primary human PTCs.
At 1, 2, 4, and 8 U/mL thrombin increased TGF-b1 se-
cretion by 141 ± 26% (NS), 183 ± 32% (P < 0.05), 276 ±
24% (P < 0.02), and 524 ± 49% (P < 0.01) of control val-
ues, respectively (Fig. 3E). The concentration of TGF-b1
in the PTC conditioned media reached about 240 pg/mL,
a secretion rate of 1.195 ng/mg protein per day, when
treated with 4 U/mL thrombin. The effect of PAR pep-
tides SFLLRN-NH2, TFLLRN-NH2, and SLIGKV-NH2
on TGF-b1 secretion was also studied. TFLLRN-NH2
failed to increase TGF-b1 secretion at any concentration
tested, SFLLRN-NH2 only significantly increased its se-
cretion at 400 lmol/L (134 ± 9% of control) (P < 0.05)
and the PAR-2 peptide SLIGKV-NH2 increased TGF-b1
secretion at each concentration tested (Table 1).
The proteolytic activity of thrombin is required for its
action on PTC
The effect of the serine protease inhibitor hirudin on
thrombin-induced PTC fibronectin secretion, DNA syn-
thesis, MCP-1 secretion, and TGF-b secretion was exam-
ined. Treatment of thrombin with hirudin (5 U/mL) prior
to its addition to the PTC abolished or partially abol-
ished thrombin-induced fibronectin secretion (thrombin
272.9 ± 63.5% vs. thrombin + hirudin 154.1 ± 34.3% of
control) (P < 0.01), DNA synthesis (thrombin 127 ± 27%
vs. thrombin + hirudin 80 ± 12% of control) (P < 0.01),
MCP-1 secretion (thrombin 233.4 ± 27% vs. thrombin +
hirudin 113.8 ± 31% of control) (P < 0.01), and TGF-b
secretion (thrombin 186 ± 18% vs. thrombin + hirudin
128 ± 11% of control) (P < 0.01) (Fig. 5).
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TGF-b1 was not responsible for thrombin-induced
fibronectin secretion
As TGF-b1 is produced by PTC in response to throm-
bin treatment and thrombin is a potent inducer of fi-
bronectin secretion by PTC, we tested the possibility that
TGF-b is mediating thrombin-induced fibronectin secre-
tion [30]. As shown in Figure 6A, a pan-specific TGF-
b neutralizing antibody was able to completely blocked
TGF-b1–induced fibronectin secretion and but was un-
able to influence thrombin-induced fibronectin secretion.
TGF-b1 is known to be potent inhibitor of PTC DNA
synthesis in PTC and thus increased DNA synthesis in
response to thrombin would not be mediated by TGF-b1
[29, 30]. However, it is possible that neutralizing TGF-b1
produced in response to thrombin would further increase
DNA synthesis. This is not the case. Figure 6B shows that
TGF-b neutralization does not alter thrombin-induced
DNA synthesis.
Thrombin-induced DNA synthesis, fibronectin secretion,
and MCP-1 secretion are not mediated by pro-MMP
activation or EGF receptor transactivation
There have been several reports which show that
thrombin can activate pro-MMPs [41, 42]. In turn MMPs
have been shown to mediate sustained release and ac-
cumulation of EGF receptor ligands, including TGF-a
and heparin-binding EGF, and thus cause EGF receptor
transactivation in certain cell types [43, 44]. To explore
whether thrombin could induce DNA synthesis, fi-
bronectin secretion, and MCP-1 secretion in PTC cultures
by MMP-mediated EGF receptor transactivation, cells
were incubated with thrombin in the presence or absence
of MMP inhibitor, GM6001 (0.1 lmol/L) or the EGF re-
ceptor kinase inhibitor, AG1478 (0.1 lmol/L). Neither
GM6001 nor AG1478 significantly inhibited DNA syn-
thesis, fibronectin secretion, or MCP-1 secretion (Fig. 7).
DISCUSSION
This investigation has demonstrated that exposure of
primary cultures of human PTC to thrombin significantly
increases DNA synthesis, fibronectin secretion, MCP-1
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 5. The effects of hirudin on thrombin-induced DNA synthesis (A),
fibronectin secretion (B and E), monocyte chemoattractant protein-
1 (MCP-1) secretion (C), and transforming growth factor-b (TGF-b)
secretion (D). Confluent, quiescent, passage 2 human PTC were treated
with or without thrombin (5 U/mL) in the presence () or absence ()
of hirudin (5 U/mL) for 24 hours. Each bar represents the mean ± SEM
for three independent experiments each performed in triplicate. ∗P <
0.01 vs. cells treated with thrombin alone; #P < 0.01 vs, control cells. (E)
A representative Western blot of fibronectin secreted by PTC treated
with either control media (C), thrombin (5 U/mL) (T), or thrombin (5
U/mL plus hirudin 5 U/mL) (T & H).
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Fig. 6. A pan-specific transforming growth factor-b (TGF-b) neutral-
izing antibody failed to influence thrombin-induced fibronectin secre-
tion. Fibronectin secretion was measured in conditioned media from
confluent, quiescent, passage 2 human proximal tubular cells (PTCs)
incubated for 24 hours in serum-free media with TGF-b1 (1 ng/mL),
or thrombin (5 U/mL) together with a pan-specific TGF-b neutralizing
antibody ( ) (15 lg/mL) or nonimmune control rabbit IgG antibody
() (15 lg/mL) or no treatment () (NIL). Each bar represents the
mean ± SEM for three independent experiments each performed in
triplicate. ∗P < 0.05 vs. control treated cells; #P < 0.05 vs. cells treated
with thrombin plus nonimmune control IgG.
secretion and TGF-b1 secretion. These responses were
all concentration-dependent and appeared to require the
proteolytic activity of thrombin. Despite the expression
of a functional thrombin receptor, PAR-1, in these cells, as
demonstrated by RT-PCR and thrombin-induced intra-
cellular calcium mobilization, the inability of the specific
PAR-1 activating peptide, TFLLRN-NH2, to mimic these
responses suggests that they are independent of PAR-
1 activation. Surprisingly, the PAR-2 activating peptide
SLIGKV-NH2 produced very similar responses to that of
thrombin. This implies that the capacity of the less spe-
cific PAR-1 activating peptide SFLLRN-NH2 to partially
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Fig. 7. The effects of matrix metalloproteinase (MMP) inhibition
and endothelial growth factor (EGF) receptor kinase inhibition on
thrombin-induced DNA synthesis, fibronectin secretion and monocyte
chemoattractant protein-1 (MCP-1) secretion. Confluent, quiescent,
passage 2 human proximal tubular cells (PTCs) were treated with or
without thrombin (5 U/mL) in the absence () or presence of MMP
inhibitor GM6001 (0.1 lmol/L) () or EGF receptor kinase inhibitor
AG1478 (0.1 lmol/L) ( ) for 24 hours. Each bar represents the mean
± SEM for three independent experiments each performed in tripli-
cate. ∗P < 0.05 vs. control-treated cells. #P > 0.05 vs. cells treated with
thrombin alone.
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reproduce these responses is due to its ability to activate
PAR-2 and is not in this case mediated via PAR-1. Fi-
nally, the mechanism of thrombin’s action on these cells
was shown not to involve MMP activation, EGF receptor
transactivation, or the autocrine action of TGF-b1.
The frequent deposition of fibrin in various renal dis-
eases, such as chronic allograft nephropathy, primary and
secondary forms of glomerulonephritis, ischemic tubular
necrosis, and obstructive nephropathy indicates that the
coagulation cascade is activated in these diseases [1–7,
18]. Fibrin is observed within the glomerular and per-
itubular capillaries, along the tubular basement mem-
brane, within the interstitial spaces, and in the glomerulus
itself [7, 8]. While there is a strong positive correlation be-
tween fibrin deposits, monocyte/macrophage infiltration
and degree of fibrosis, the exact mechanism and relevance
of this to the pathogenic processes are unclear [45, 46].
The production of active thrombin from prothrom-
bin with the subsequent conversion of fibrinogen to fib-
rin represents the final stage of the coagulation cascade.
Thrombin associated with fibrin clots can remain active
and protected from inhibitors over prolonged periods.
Subsequent fibrinolysis can result in thrombin release [18,
47, 48]. The degradation of fibrin is regulated predomi-
nantly by the activity of the protease plasmin, which is,
in turn, tightly controlled by plasminogen activator in-
hibitors (PAI-1). Enhanced levels of PAI-1 are reported
to contribute to persistent fibrin deposition and also in-
terstitial fibrosis [4, 5, 49].
Tissue factor is the main physiologic initiator of blood
coagulation and its abnormal or elevated expression
within the kidney in disease conditions appears to be re-
sponsible for the activation of the coagulation cascade
and fibrin deposition [6, 50]. Activated infiltrating mono-
cytes/macrophages are also known to express elevated
tissue factor and there are also a number of reports that
demonstrate macrophages can express a prothrombinase
activity and have thrombin-like activity [51–53].
In our PTC cultures, mRNA for two of the three known
thrombin receptors, PAR-1 and PAR-3, were expressed.
In addition, mRNA for PAR-2, a receptor activated by
other serine proteases such as trypsin and tryptase, was
expressed. Previous studies which examined PAR-1 ex-
pression in PTC have differed. In one study where im-
munohistochemistry and in situ-hybridisation were used,
PAR-1 expression could not be detected [14]. In contrast,
the presence of PAR-1 in HK-2 cells and normal kidney
sections has been reported and elevated PAR-1 expres-
sion found in chronic allograft nephropathy [7, 18]. They
showed that PAR-1 immunoactivity was predominantly
located on the basolateral aspect of PTC but also to some
extent on the luminal side.
Because of the conflicting evidence of these studies,
precautions were taken to eliminate possible false posi-
tive results. PAR-1 mRNA expression was assessed using
two different sets of PAR-1–specific primers, the chance
of genomic DNA contamination of RNA was reduced
by inclusion of a DNase treatment step, and samples for
RT-PCR were included in which no reverse transcriptase
was present at the RT stage. PAR-3 is reported to lack
an intracellular signaling capacity and is thought, at least
in mouse platelets, to be a cofactor for PAR-4 [12]. The
relevance to PAR-3 expression in the absence of PAR-4
expression is unclear.
To confirm that functional PAR receptors are ex-
pressed by PTC in culture, cells were challenged
with PAR agonists and calcium mobilization moni-
tored. Thrombin and the PAR peptides TFLLRN-NH2,
SFLLRN-NH2, and SLIGKV-NH2 all induced rapid in-
creases in intracellular Ca2+, suggesting that functional
PAR-1 and PAR-2 are expressed by PTC in culture.
The PAR-2–specific peptide, SLIGKV-NH2, induced the
largest rise in intracellular calcium while the PAR-1–
specific peptide, TFLLRN-NH2, produced signals at
about 34% of SLIGKV-NH2. SFLLRN-NH2 which has
been shown to activate both PAR-1 and PAR-2 [54] pro-
duced a larger signal at 52% of that due to SLIGKV-NH2.
A DNA synthetic response to thrombin has been doc-
umented in a variety of different cell types, including
fibroblasts, airway and vascular smooth muscle cells, ker-
atinocytes, and mesangial cells [14, 55–58]. There has
been one report, that we are aware of, that demonstrates
that PTCs undergo DNA synthesis in response to throm-
bin [7]. In this study conducted on the SV40 transformed
PTC line, HK-2, it was found that thrombin at 5 U/mL
induces a greater than 300% increase in DNA synthe-
sis, which was accompanied by similar increases in cell
numbers. Our results support these findings but are more
likely to represent PTC in vivo because of our use of low
passage, primary nontransformed cells.
Ischemia is a common insult in acute renal disease and
is often accompanied by activation of the coagulation
pathway. It has been suggested that thrombin represents
a tubule growth factor responsible for the initial steps
toward cellular recovery and regeneration after tubule
injury [7]. On the other hand, tubule DNA synthesis and
proliferation is often seen in the initial stages of tubule
cell activation, inflammation, and fibrosis and can be me-
diated by fibrogenic growth factors such as insulin-like
growth factor (IGF-1) [59]. Clearly, there is a fine-line be-
tween the benefits of regeneration after tubule injury and
the prolonged uncontrolled inflammatory/proliferative
responses derived from repeated cycles of cellular injury.
It has been reported that the ability of thrombin to
stimulate DNA synthesis in various cell types is medi-
ated indirectly by the induction and autocrine action of
a range of growth factors and cytokines. These include
TGF-b , PDGF, prostaglandins E2, epiregulin, heparin-
binding EGF, basic FGF (bFGF), and vascular endothe-
lial growth factor (VEGF). To exclude all these growth
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factors and cytokines as mediators of the DNA synthetic
response seen here would be difficult. The enhanced se-
cretion of TGF-b1 noted here in response to thrombin
would not account for the enhanced DNA synthesis ob-
served as TGF-b1 inhibits DNA synthesis in PTC [29,
30]. On the other hand the fibronectin secretion could be
mediated by the autocrine action of TGF-b1.
Fibronectin is a noncollagenous ECM glycoprotein
that can be produced by a wide variety of cell types.
It is known to play an important part in wound heal-
ing, including clot formation, cell adhesion and migra-
tion, and matrix deposition. It is a chemoattractant
for fibroblasts, keratinocytes, epithelial cells, and mono-
cyte/macrophages, a scaffold protein for endothelial orga-
nization and template for collagen deposition [60]. In the
present study, thrombin-induced fibronectin could con-
ceivably be involved in any of these processes.
We have previously reported that primary PTCs
secrete significant amounts of fibronectin and that fibro-
genic cytokines such as TGF-b1 and interleukin-1b (IL-
1b) can greatly enhance its production [30]. This increase
was predominantly in the secreted form. The amount of
cell-associated fibronectin was significantly increased by
IL-1b in renal cortical fibroblasts but not PTCs. In the
present study thrombin induced a similar response to
these cytokines. Immunoblotting demonstrated that the
fibronectin migrated as a single band with an apparent
molecular weight of 220 kD, and evidence of fibronectin
fragmentation was not observed.
Several reports have shown that thrombin is able
to cleave fibronectin [36, 61]. The possibility that fi-
bronectin present in the conditioned culture media does
not represent increased levels of synthesis and secre-
tion but rather just proteolytic release of cell associ-
ated fibronectin was considered. In this case increased
fibronectin in the media may be accompanied by reduced
amount of cell-associated fibronectin. Immunoblotting
demonstrated that increased fibronectin in the media was
coupled with decreased cell-associated fibronectin. How-
ever, this could not account for all of the fibronectin
observed in the media after thrombin treatment. It is
probable that increased synthesis and secretion as well
as the proteolytic release of cell-associated fibronectin
are involved. The finding that hirudin is able to block fi-
bronectin secretion would be compatible with this result.
Previous studies in mesangial cells demonstrated that
thrombin can enhance TGF-b1 production [20]. We
found a similar response to thrombin in PTC. As TGF-b
can induce fibronectin secretion by PTC in culture, we
tested the possibility that this TGF-b might be responsi-
ble for the action of thrombin. A pan-specific TGFb neu-
tralizing antibody was unable to influence this response to
thrombin while efficiently blocking the response to TGF-
b1. TGF-b1 may be secreted in an inactive form but this
does not preclude its ability to act in a paracrine/autocrine
fashion in vivo where activating mechanisms would exist.
Alternatively, the amount of secreted TGF-b1 may not
have been enough to stimulate fibronectin secretion in
these cells.
MCP-1 is a powerful monocyte chemotactic molecule
that can be produced by a range of renal cell types, includ-
ing tubule epithelium, mesangial, and endothelial cells
[40]. Infiltrating monocytes/macrophages in turn secrete
cytokines and chemokines, which promote inflammation
and fibrosis. However, not only is MCP-1 a chemotactic
agent but it has a range of other actions, which are only
starting to be described. MCP-1 is able to directly activate
tubular cells in vitro, promoting cytokine production (e.g.,
IL-6), and adhesion molecule expression [e.g., intercellu-
lar adhesion molecule-1 (ICAM-1)], via a G protein, pro-
tein kinase C, nuclear factor-kappaB (NF-kB)-dependent
mechanism [40]. Its importance in renal disease and
in particular the development of interstitial lesions is
clearly demonstrated in MCP-1 knockout mice which ex-
hibit less tubulointerstitial lesions [62]. Increased mono-
cyte/macrophage infiltration is also a common feature of
renal disease and correlates strongly with the presence of
fibrin [45]. Our finding which demonstrated that throm-
bin enhances MCP-1 secretion by PTC supports the view
that thrombin enhances MCP-1–induced infiltration of
inflammatory cells in interstitial renal disease. As both
thrombin and fibrin have also been shown to be chemo-
tactic for monocytes together with MCP-1 and fibronectin
the chemotactic signal for monocyte/macrophages infil-
tration would be amplified.
The inability of the PAR-1–specific peptide, TFLLRN-
NH2, to reproduce the actions of thrombin examined
here, indicates that these responses are not mediated
solely by PAR-1 activation. This is despite the presence
of functional PAR-1 on PTC and the apparent require-
ment for thrombin’s proteolytic activity. That the peptide
SFLLRN-NH2 elicits some of the responses produced
by thrombin can most readily be explained by cross-
activation of PAR-2 [54]. The other thrombin receptor
identified in our PTC cultures was PAR-3. This receptor
is not thought to mediate biologic responses in cells in-
dependently of another thrombin receptor, PAR-4. We
failed to find PAR-4 expression in our PTC cultures and
thus PAR-3 is unlikely to contribute to the responses
to thrombin observed here. These results imply that a
non-PAR thrombin receptor is involved. A number of
publications have clearly demonstrated that a noncat-
alytic domain of thrombin, a site that is responsible for
its high affinity binding to cell surfaces, can induce bi-
ologic responses that are distinct from those produced
by its proteolytic active site [63–65]. Interestingly, Nor-
fleet, Bergmann, and Carney [64] have shown that a 23
amino acid thrombin peptide which lacks any proteolytic
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activity can induce mitogenesis and chemotaxis in cul-
tured cells and dermal wound healing in animals. A dual
signaling model for thrombin activity has been proposed
whereby proteolytic cleavage and nonproteolytic binding
are required for a full physiologic response [64, 65]. Our
findings are compatible with this model. The thrombin
induced responses observed here may well require an
input from both PAR-1 and thrombin’s nonproteolytic
binding site. Activation of PAR-1 by TFLLRN-NH2 is
not sufficient.
In our studies, hirudin, which specifically blocks throm-
bin’s proteolytic activity, was able to block thrombin-
induced DNA synthesis and MCP-1, fibronectin, and
TGF-b1 secretion. As hirudin is a fairly large molecule,
it is possible that the noncatalytic domain of thrombin
is also blocked by hirudin and that this is the mecha-
nism by which it abrogates the responses of these cells
to thrombin. Further studies are warranted to elucidate
this possibility. Two recent publications support the pos-
sibility of further thrombin receptors. In one study in
airway smooth muscle cells, thrombin mediated both
growth and proinflammatory actions by a non-PAR-1,
G protein–coupled receptor-dependent mechanism [66].
The other showed that thrombin’s antiapoptotic activ-
ity in osteoblasts involves thrombin-induced secretion of
survival factors but not PAR activation [67].
Another potential mechanism by which thrombin
induces the proinflammatory and proproliferative re-
sponses seen here, involves pro-MMP activation and
EGF receptor transactivation. Lafleur et al [41] have
shown that thrombin can activate pro-MMP-2 in human
umbilical vascular endothelial cells (HUVEC) [41] and
it is well documented that EGF receptor ligands, includ-
ing heparin-binding EGF and TGF-a, can be produced
in various cell types by a MMP-dependent mechanism
[43, 44]. In this study, GM6001 (a broad-spectrum MMP
inhibitor) and AG1478 (a potent EGF receptor kinase
inhibitor) were unable to influence thrombin-induced
DNA synthesis, fibronectin secretion, or MCP-1 secre-
tion suggesting some alternative mechanism must exist.
It is possible that other growth factors involved in these
responses are produced by PTC in response to thrombin
[21, 22].
CONCLUSION
We have demonstrated that the serine protease throm-
bin stimulates proinflammatory and fibroproliferative
responses in primary cultures of human PTC. These
responses, which appear to be mediated by a PAR-1–
independent mechanism, may help explain the extent of
tubulointerstitial fibrosis observed in renal diseases as-
sociated with fibrin deposition. Although the design of
therapies that specifically block PAR-1 activation in the
kidney may well prove to be useful strategies to limit the
progression of renal fibrosis, combined approaches that
also consider the inhibition of serine protease activity,
may well have greater potential.
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